Highlights•The most common reason for the failure of the cancer treatment is the evolving
drug resistance.•The ABC transporters mainly P-gp, BCRP and MRP1 are responsible for …

Multidrug resistance (MDR) triggered by ATP binding cassette (ABC) transporter such as
ABCB1, ABCC1, ABCG2 limited successful cancer chemotherapy. Unfortunately, no …

The overexpression of the human ATP-binding cassette (ABC) transporters in cancer cells is
a common mechanism involved in developing multidrug resistance (MDR). Unfortunately …

The multidrug resistance (MDR) phenomenon in cancer cells is the major obstacle leading
to failure of chemotherapy accompanied by the feature of intractable and recurrence of …

MET receptor has emerged as a druggable target across several human cancers. Agents
targeting MET and its ligand hepatocyte growth factor (HGF) including small molecules such …

Background: Dual-targeting in cancer treatment by a single drug is an unconventional
approach in relation to drug combinations. The rationale for the development of …

Compared with other breast cancer subtypes, triple-negative breast cancer (TNBC) is
associated with relatively poor outcomes due to its metastatic propensity, frequent failure to …

Overexpression of the multidrug resistance (MDR)-related protein P-glycoprotein (PGP1),
which actively extrudes chemotherapeutic agents from cells and significantly decreases the …

In 2023, colorectal cancer (CRC) is the third most diagnosed malignancy and the third
leading cause of cancer death worldwide. At the time of the initial visit, 20% of patients …

Background: One of the main chemotherapeutic drugs used on a routine basis in patients
with metastatic colorectal cancer ((m) CRC) is the topoisomerase-1 inhibitor, irinotecan …